Haleon (NYSE:HLN) Upgraded by Zacks Research to Hold Rating

Haleon (NYSE:HLN) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Several other analysts have also issued reports on HLN. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of NYSE:HLN opened at $9.87 on Wednesday. The business’s 50-day moving average is $9.67 and its 200 day moving average is $9.82. The firm has a market capitalization of $43.47 billion, a P/E ratio of 25.31, a P/E/G ratio of 1.97 and a beta of 0.12. Haleon has a 1 year low of $8.65 and a 1 year high of $11.28. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC bought a new stake in shares of Haleon during the fourth quarter valued at about $187,000. AQR Capital Management LLC lifted its position in Haleon by 22.5% in the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after buying an additional 17,720 shares in the last quarter. Focus Partners Wealth lifted its stake in Haleon by 7.6% in the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after acquiring an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC boosted its stake in Haleon by 11.6% during the 2nd quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.